FierceBiotech2h
Achilles drops cell therapy program, braces for layoffs after missing 'commercial viability' goals
Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...
FierceBiotech8h
From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform
GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...
FierceBiotech3h
Vanda receives FDA rejection, issues fiery response against ‘conclusory’ refusal
Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 ...
FierceBiotech6h
Inflammation-focused Upstream set to join growing trickle of biotech IPOs
The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...
FierceBiotech18h
NIH grants up to $100M yearly for pandemic preparedness network
With COVID-19 still spreading and mpox emerging as a public health emergency of international concern, the National ...